Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier™ in Early-Stage Estrogen Receptor-Positive Breast Cancer
Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier™ in Early-Stage Estrogen Receptor-Positive Breast Cancer
复制标题
DOI：
10.1634/theoncologist.2012-0007
复制
发表时间：
2012-04-01
期刊：
影响因子：
5.8
通讯作者：
Pusztai, Lajos
中科院分区：
文献类型：
--
作者：
Kelly, Catherine M.;Bernard, Philip S.;Pusztai, Lajos
目的.在同一人群中比较PAM 50乳腺癌内在分类器T和Oncotype DX复发评分（RS）的风险分配。从151例雌激素受体（ER）（+）I-II期乳腺癌中提取RNA，并使用PAM 50“内在”亚型检测分析基因表达。108例病例具有完整的分子信息; 103例（95%）被分类为管腔A（n = 76）或管腔B（n = 27）。92%（n = 98）具有低（n = 59）或中等（n = 39）RS。在管腔A型癌中，70%的患者（n = 53）具有低RS，其余患者（n = 23）具有中等RS。在管腔B癌中，RS评分为9例高（33%），13例中等（48%）。几乎所有具有高RS的癌症都被归类为腔B（90%，n = 9）。在两种测定中，通过定量聚合酶链反应，一种高RS癌症被鉴定为基底样癌症，并且ER/ESR 1和人表皮生长因子受体2（HER 2）表达较低。大多数低RS病例为管腔A型（83%，n = 53）。重要的是，一半的中间RS癌被PAM 50重新分类为低风险的管腔A亚型。对于高（即，管腔B或RS > 31）和低（即，管腔B或RS < 18）预后风险分配，但PAM 50将更多患者分配到低风险类别。大约一半的中间RS组被PAM 50重新分类为管腔A。肿瘤学家2012;17：492-498
Purpose. To compare risk assignment by PAM50 Breast Cancer Intrinsic Classifier T and Oncotype DX_Recurrence Score (RS) in the same population.Methods. RNA was extracted from 151 estrogen receptor (ER)(+) stage I-II breast cancers and gene expression profiled using PAM50 "intrinsic" subtyping test.Results. One hundred eight cases had complete molecular information; 103 (95%) were classified as luminal A (n = 76) or luminal B (n = 27). Ninety- two percent (n = 98) had a low (n = 59) or intermediate (n = 39) RS. Among luminal A cancers, 70% had low (n = 53) and the remainder (n = 23) had an intermediate RS. Among luminal B cancers, nine were high (33%) and 13 were intermediate (48%) by the RS. Almost all cancers with a high RS were classified as luminal B (90%, n = 9). One high RS cancer was identified as basal-like and had low ER/ESR1 and low human epidermal growth factor receptor 2 (HER2) expression by quantitative polymerase chain reaction in both assays. The majority of low RS cases were luminal A (83%, n = 53). Importantly, half of the intermediate RS cancers were re-categorized as low risk luminal A subtype by PAM50.Conclusion. There is good agreement between the two assays for high (i.e., luminal B or RS > 31) and low (i.e., luminal B or RS < 18) prognostic risk assignment but PAM50 assigns more patients to the low risk category. About half of the intermediate RS group was reclassified as luminal A by PAM50. The Oncologist 2012;17:492-498